AI Diagnostics Face Two-Year Reimbursement Hurdles Despite Cost Savings
AI-powered diagnostic tests, even those offering significant cost reductions, face substantial delays in gaining regulatory approval and reimbursement. David Spetzler of a diagnostic company highlighted a breast cancer early recurrence test that could halve costs compared to existing options, yet is